Biovectra Enhances Manufacturing Capacity and Flexibility with ABEC’s CSR® Large-Scale, Single-Use Microbial Fermentation Technology

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing and BIOVECTRA, a CDMO specializing in clinical-to-commercial scale production of high-quality regulated Biologics, Active Pharmaceutical Ingredients, and intermediates, today announced ABEC will design, manufacture, and install CSR single-use microbial fermentation solutions at BIOVECTRA’s manufacturing facility in Windsor, Nova Scotia, Canada. ABEC’s fast-track manufacturing schedule will enable BIOVECTRA to be fully operational by Q2, 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005025/en/

ABEC 1,000L CSR® Single-Use Fermenter (Photo: Business Wire)

The seamless integration of ABEC CSR single-use fermentation solutions will enhance BIOVECTRA’s high growth microbial fermentation processes and provide fast turnaround product to product and between batches. The addition of large-scale single-use fermentation capability provides BIOVECTRA customers with greater flexibility, faster turnaround and higher capacity utilization. ABEC is also supplying BIOVECTRA CSR single-use disposable containers (DCs) from its two in-house ISO-7 cleanroom manufacturing facilities in Bethlehem, Pa. and Fermoy, County Cork, Ireland. These facilities, as well as ABEC’s qualification of multiple single-use instrument and component suppliers, ensure a robust supply chain and timely delivery to meet BIOVECTRA’s rapid time to market needs.

“BIOVECTRA will be the first Canadian CDMO to offer single-use, microbial fermentation at 1,000L scale,” said Heather Delage, Chief Commercial Officer, BIOVECTRA. “ABEC’s 100L and 1,000L fermentation suites, complement our fixed asset base in biologics fermentation, bringing our customers improved economies of scale and greater process flexibility.”

“ABEC continues to lead the industry advancing bioprocess manufacturing with large-scale single-use process solutions,” said Scott Pickering, ABEC CEO and Chairman. “We are excited to help BIOVECTRA expand their capability, offering single-use, microbial fermentation at large-scale, and we look forward to supporting their continued success.”

About ABEC

Since 1974, ABEC has been a global leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. The majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. Visit abec.com, email [email protected].

About BIOVECTRA

BIOVECTRA is a forward-thinking, North American contract development and manufacturing organization with full-service, clinical-to-commercial scale GMP outsourcing solutions for critical raw materials, intermediates, active pharmaceutical ingredients, and biologic drug substances. An innovative and reliable partner with a strong regulatory history and commercial supply experience, BIOVECTRA has a 50-year track record of delivering: Biologics, Synthetic small molecules, Fermented small molecules, Highly potent APIs, and Bioreagents. We care about making better therapeutics. For more information about BIOVECTRA, visit www.BIOVECTRA.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005025/en/